Sustex is a testosterone blend consisting of a mix of propionate, phenylpropionate, isocaproate, and decanoate esters. Because of the mix of different esters, Sustex has improved pharmacokinetics with the fast action of propionates and the prolonged action of longer isocaproate and decanoate esters, providing a more stable concentration of testosterone in the blood over a longer period of time.
Esterification of the 17-beta-hydroxy group by different esters can prolong the action of testosterone, because testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus Sustex can be given at intervals of two to four weeks.
View IA Superpharma USA-Lite all product range by visiting the Shop Page.
|SUSTEX 2: EACH ML CONTAINS:|
|Testosterone Decanoate||BP||100 mg|
|Grape Seed Oil||BP||q.s.|
Dosage and administration:
Half life between 24 hours and 10 days
Adult dose (male): 200mg-1200mg EOD, ETD or EFD by intramuscular injection
Adult dose (female): 25-100mg EOD, ETD or EFD by intramuscular injection
NOTE: This product is designed to be injected with a frequency that matches the shortest ester (Testosterone Propionate). This product will need to be injected every second day to avail of its full effects and any blood drawn for testing will need to be taken within 48 hours of the previous injection
Average Cycle Length: 4-12weeks following an EOD injection pattern. Male hormone replacement therapy sees 1ml of Sus250mg injected every three weeks ongoing
Anabolic #: 100:100:100:100:125
Androgenic #: 100:100:100:100:37
Bioavailability: Estimated at 100%
CAS Name: androst-4-en-3-one, 17-[(1-oxoheptyl)-oxy]-(17)-androst-4-en-3-one
CAS Name: 17-(3-cyclopentyl1-oxopropoxy)-(17)- 17-(1-Oxopropoxy)
CAS Name: (17b)-androst-4-en-3-one 17b-Hydroxyandrost-4-en-3-one decanoate
Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia. Androgens are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant.
During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). In males: at large doses of exogenous androgens, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH). In females: virilization effects.